- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA Releases Statement on Prescription Drug Pricing Reduction Act
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act. While COA supports certain provisions in the package, including encouraging a healthy and competitive biosimilars market, transparency around pharmacy benefit managers, and changes to grandfathered site-neutral payments for hospitals, there are some provisions COA is opposed to. For example: the proposal to include support from patient assistance programs in the calculation of Average Sales Price, which is the basis for Medicare Part B drug reimbursement.
According to Okon, the provision would lead to drug manufacturers to reduce or eliminate programs. Read the full press release.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
